MX2021011110A - Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana. - Google Patents
Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.Info
- Publication number
- MX2021011110A MX2021011110A MX2021011110A MX2021011110A MX2021011110A MX 2021011110 A MX2021011110 A MX 2021011110A MX 2021011110 A MX2021011110 A MX 2021011110A MX 2021011110 A MX2021011110 A MX 2021011110A MX 2021011110 A MX2021011110 A MX 2021011110A
- Authority
- MX
- Mexico
- Prior art keywords
- plasma kallikrein
- hereditary angioedema
- kallikrein inhibitors
- angioedema attack
- treating hereditary
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
En la presente se proporcionan métodos para tratar y prevenir el ataque de angioedema hereditario en ciertas subpoblaciones de pacientes humanos cuya enfermedad se controla bien en un primer período de tratamiento, que implica el uso de un anticuerpo que se une a calicreína plasmática humana. Estos pacientes se pueden someter a una dosis reducida del anticuerpo y/o un intervalo de dosificación prolongado en un segundo período de tratamiento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962818189P | 2019-03-14 | 2019-03-14 | |
PCT/US2020/022535 WO2020186132A1 (en) | 2019-03-14 | 2020-03-13 | Treating hereditary angioedema attack with reduced dosage of antibodies binding to human plasma kallikrein |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021011110A true MX2021011110A (es) | 2022-01-19 |
Family
ID=70228815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021011110A MX2021011110A (es) | 2019-03-14 | 2020-03-13 | Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20200317815A1 (es) |
EP (1) | EP3938404A1 (es) |
JP (1) | JP2022525164A (es) |
KR (1) | KR20210142006A (es) |
AU (1) | AU2020237259A1 (es) |
CA (1) | CA3133576A1 (es) |
MX (1) | MX2021011110A (es) |
TW (1) | TW202100561A (es) |
WO (1) | WO2020186132A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2688093T3 (es) | 2010-01-06 | 2018-10-30 | Dyax Corp. | Proteínas de unión a calicreína plasmática |
WO2012094587A1 (en) | 2011-01-06 | 2012-07-12 | Dyax Corp. | Plasma kallikrein binding proteins |
JP2016513682A (ja) | 2013-03-15 | 2016-05-16 | ダイアックス コーポレーション | 抗血漿カリクレイン抗体 |
BR112016022318A2 (pt) | 2014-03-27 | 2017-10-31 | Dyax Corp | método, composição farmacêutica para uso no tratamento de doenças de retina e uso de um anticorpo |
US11286307B2 (en) | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
JP2023510854A (ja) * | 2020-01-13 | 2023-03-15 | 武田薬品工業株式会社 | 小児遺伝性血管性浮腫発作を治療するための血漿カリクレイン阻害剤及びその使用 |
CN114790245A (zh) * | 2021-01-25 | 2022-07-26 | 成都康弘生物科技有限公司 | 一种抗体及其用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
LU91067I2 (fr) | 1991-06-14 | 2004-04-02 | Genentech Inc | Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines |
US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
JP3805785B2 (ja) | 1994-01-11 | 2006-08-09 | ダイアックス コープ. | カリクレイン阻害クニッツドメイン蛋白質およびその相同体 |
PT1531791E (pt) | 2002-06-07 | 2010-12-16 | Dyax Corp | Prevenção e redução da isquémia |
US11286307B2 (en) * | 2015-12-11 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack |
-
2020
- 2020-03-13 US US16/817,671 patent/US20200317815A1/en active Pending
- 2020-03-13 WO PCT/US2020/022535 patent/WO2020186132A1/en unknown
- 2020-03-13 EP EP20718034.0A patent/EP3938404A1/en active Pending
- 2020-03-13 AU AU2020237259A patent/AU2020237259A1/en active Pending
- 2020-03-13 TW TW109108355A patent/TW202100561A/zh unknown
- 2020-03-13 KR KR1020217033056A patent/KR20210142006A/ko unknown
- 2020-03-13 MX MX2021011110A patent/MX2021011110A/es unknown
- 2020-03-13 CA CA3133576A patent/CA3133576A1/en active Pending
- 2020-03-13 JP JP2021555282A patent/JP2022525164A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TW202100561A (zh) | 2021-01-01 |
JP2022525164A (ja) | 2022-05-11 |
WO2020186132A1 (en) | 2020-09-17 |
AU2020237259A1 (en) | 2021-10-14 |
US20200317815A1 (en) | 2020-10-08 |
EP3938404A1 (en) | 2022-01-19 |
CA3133576A1 (en) | 2020-09-17 |
KR20210142006A (ko) | 2021-11-23 |
WO2020186132A8 (en) | 2020-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021011110A (es) | Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana. | |
PH12018502355A1 (en) | Enzyme inhibitors | |
MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
UA118453C2 (uk) | Спосіб лікування пухлин у пацієнта | |
UA94899C2 (ru) | Фиксированное дозирование антител к her | |
MX2022010357A (es) | Anticuerpos inhibidores de anti-pcsk9 para el tratamiento de pacientes con hiperlipidemia que se someten aferesis de lipoproteina. | |
PH12020551597A1 (en) | Treatment of hidradenitis suppurativa using jak inhibitors | |
MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
MX2019009227A (es) | Métodos para tratar cáncer con inhibidores de hsp90. | |
MX2019003134A (es) | Terapia de combinacion. | |
WO2018208793A8 (en) | S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY | |
BR112018011622A2 (pt) | método para tratar ataque de angioedema hereditário (hae) ou reduzir a taxa de ataque de hae | |
WO2018102687A3 (en) | Combination therapy for treating cancer | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
MX2021009051A (es) | Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular. | |
PH12017500392A1 (en) | Medical treatments based on anamorelin | |
MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
MX2022000545A (es) | Inhibidores de enzimas. | |
PH12020500096A1 (en) | Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor | |
EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
WO2019055776A3 (en) | Compositions and methods for treatment of diseases involving cxcl1 function | |
MX2019004200A (es) | Terapia de combinacion. | |
EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
MX2021004138A (es) | Metodos y formulaciones para tratar nauseas y vomito inducidos por quimioterapias. |